VeriSign Free cash flow decreased by 7.0% to $265.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.1%, from $285.50M to $265.20M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 9.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $124.90M | $244.90M | $192.80M | $200.50M | $138.70M | $255.30M | $209.20M | $253.30M | $138.80M | $216.70M | $199.20M | $253.50M | $151.20M | $247.80M | $222.00M | $285.50M | $194.70M | $303.00M | $285.10M | $265.20M |
| QoQ Change | — | +96.1% | -21.3% | +4.0% | -30.8% | +84.1% | -18.1% | +21.1% | -45.2% | +56.1% | -8.1% | +27.3% | -40.4% | +63.9% | -10.4% | +28.6% | -31.8% | +55.6% | -5.9% | -7.0% |
| YoY Change | — | — | — | — | +11.0% | +4.2% | +8.5% | +26.3% | +0.1% | -15.1% | -4.8% | +0.1% | +8.9% | +14.4% | +11.4% | +12.6% | +28.8% | +22.3% | +28.4% | -7.1% |